Medsider: Learn from MedTech and HealthTech Experts

How to Navigate Clinical Trials and Fundraising Challenges: Interview with Eyevensys CEO Patricia Zilliox

January 19, 2022 Scott Nelson
Medsider: Learn from MedTech and HealthTech Experts
How to Navigate Clinical Trials and Fundraising Challenges: Interview with Eyevensys CEO Patricia Zilliox
Show Notes

In this episode of Medsider Radio, we’re sitting down with Patricia Zilliox, wo has spent her entire career working in ophthalmology, including 30 years at American-Swiss medical company Alcon. In 2017, Patricia became CEO of Eyevensys, a biotech company in the clinical stage of making a drug delivery system to fight various eye diseases. 

In this interview, Patricia gives advice for navigating the complicated world of regulatory affairs, the dos and don’ts of planning clinical trials, and why raising capital is the most frustrating part of her job.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. 

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Patricia if you'd rather read it instead.